199 related articles for article (PubMed ID: 26471831)
1. mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition.
Massey AJ; Stephens P; Rawlinson R; McGurk L; Plummer R; Curtin NJ
Mol Oncol; 2016 Jan; 10(1):101-12. PubMed ID: 26471831
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.
Wayne J; Brooks T; Massey AJ
Oncotarget; 2016 Dec; 7(51):85033-85048. PubMed ID: 27829224
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel, in vivo active Chk1 inhibitors utilizing structure guided drug design.
Massey AJ; Stokes S; Browne H; Foloppe N; Fiumana A; Scrace S; Fallowfield M; Bedford S; Webb P; Baker L; Christie M; Drysdale MJ; Wood M
Oncotarget; 2015 Nov; 6(34):35797-812. PubMed ID: 26437226
[TBL] [Abstract][Full Text] [Related]
5. γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.
Rawlinson R; Massey AJ
BMC Cancer; 2014 Jul; 14():483. PubMed ID: 24996846
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
7. DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1.
Selvarajah J; Elia A; Carroll VA; Moumen A
Oncotarget; 2015 Jan; 6(1):427-40. PubMed ID: 25460505
[TBL] [Abstract][Full Text] [Related]
8. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells.
Bryant C; Scriven K; Massey AJ
Mol Cancer; 2014 Jun; 13():147. PubMed ID: 24913641
[TBL] [Abstract][Full Text] [Related]
10. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
12. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
14. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
[TBL] [Abstract][Full Text] [Related]
15. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
Pan Y; Ren KH; He HW; Shao RG
Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
[TBL] [Abstract][Full Text] [Related]
18. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
Wu L; Zhang J; Wu H; Han E
Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
[TBL] [Abstract][Full Text] [Related]
19. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
20. Repair-independent functions of DNA-PKcs protect irradiated cells from mitotic slippage and accelerated senescence.
Liu Y; Efimova EV; Ramamurthy A; Kron SJ
J Cell Sci; 2019 Jul; 132(13):. PubMed ID: 31189537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
